Top Markets
#1 Cash Cat Cash Cat +12.09%
#2 Siacoin Siacoin +11.51%
#3 0G 0G +9.75%
#4 Seeker Seeker +9.52%
#5 Arbitrum Arbitrum +8.67%
#6 Metis Metis +5.28%
#7 Story Story +3.96%
#8 MarsCoin MarsCoin +3.88%
#9 Cryptopia Cryptopia +3.87%
#10 Metronome Synth ETH Metronome Synth ETH +3.75%
Coin of the day
Cash Cat Cash Cat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
Clasificación en acciones #14050
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Precio por acción
$0.88012714
Última sincronización: 2026-08-31
Capitalización bursátil
$439.58M
Cambio (1 día)
-4.01%
Cambio (1 año)
1,131.97%
País
FR
Comercio Valerio Therapeutics S.A. (ALVIO)

Categoría

Healthcare
Ingresos de Valerio Therapeutics S.A. (ALVIO)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de Valerio Therapeutics S.A., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Valerio Therapeutics S.A. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH